Ignite Creation Date:
2025-12-25 @ 12:18 AM
Ignite Modification Date:
2026-01-07 @ 11:02 AM
Study NCT ID:
NCT03499158
Status:
COMPLETED
Last Update Posted:
2018-04-17
First Post:
2018-04-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Terminal Latency Index, Residual Latency and Median Ulnar F Latency Difference in Carpal Tunnel Syndrome
Sponsor:
ASLIHAN UZUNKULAOGLU
Organization:
Study Overview
Official Title:
Role of Terminal Latency Index, Residual Latency and Median Ulnar F Latency Difference in Carpal Tunnel Syndrome
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Terminal latency index, residual latency and median ulnar F latency difference in carpal tunnel syndrome are specific parameters for the diagnosis
Detailed Description:
Carpal tunnel syndrome is the most common compression neuropathy. This study was performed to determine the value of terminal latency index, residual latency and median ulnar F latency difference to investigate their sensitivity and specificity in the diagnosis of this syndrome.
We retrospectively determined the 160 patients. We evaluated the nerve conduction studies of patient and healthy arms. We recorded all nerve conduction study values.
We retrospectively determined the 160 patients. We evaluated the nerve conduction studies of patient and healthy arms. We recorded all nerve conduction study values.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: